Development of Edaravone Ionic Liquids and Their Application for the Treatment of Cerebral Ischemia/Reperfusion Injury
Open Access
- 8 May 2023
- journal article
- research article
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 20 (6) , 3115-3126
Abstract
Preparation of the ionic liquid (IL) form of active pharmaceutical ingredients (APIs), termed API-IL, has attracted attention because it can improve upon certain disadvantages of APIs, such as poor water solubility and low stability. Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one) is a clinically approved cerebroprotective agent against ischemic stroke and amyotrophic lateral sclerosis, while new formulations that enable improvement of its physicochemical properties and biodistribution are desired. Herein, we report a newly developed API-IL of edaravone (edaravone-IL), in which edaravone is used as an anionic molecule. We investigated the physicochemical properties of edaravone-IL and its therapeutic effect against cerebral ischemia/reperfusion (I/R) injury, a secondary injury after an ischemic stroke. Among the cationic molecules used for edaravone-IL preparation, the IL prepared with tetrabutylphosphonium cation existed as a liquid at room temperature, and significantly increased the water solubility of edaravone without decreasing its antioxidative activity. Importantly, edaravone-IL formed negatively charged nanoparticles upon suspension in water. Intravenous administration of edaravone-IL showed significantly higher blood circulation time and lower distribution in the kidney compared with edaravone solution. Moreover, edaravone-IL significantly suppressed brain cell damage and motor functional deficits in model rats of cerebral I/R injury and showed comparable cerebroprotective effect to edaravone. Taken together, these results suggest that edaravone-IL could be a new form of edaravone with superior physicochemical properties and could be useful for the treatment of cerebral I/R injury.Keywords
Funding Information
- Japan Society for the Promotion of Science (21K18065)
This publication has 54 references indexed in Scilit:
- Amelioration of cerebral ischemia–reperfusion injury based on liposomal drug delivery system with asialo-erythropoietinJournal of Controlled Release, 2012
- Estimation of antiradical properties of antioxidants using DPPH assay: A critical review and resultsFood Chemistry, 2012
- Crystalline vs. Ionic Liquid Salt Forms of Active Pharmaceutical Ingredients: A Position PaperPharmaceutical Research, 2010
- A novel administration route for edaravone: I. Effects of metabolic inhibitors on skin permeability of edaravoneInternational Journal of Pharmaceutics, 2009
- Determinants for the prognosis of acute renal disorders that developed during or after treatment with edaravoneClinical and Experimental Nephrology, 2009
- Hydroformylation in Room Temperature Ionic Liquids (RTILs): Catalyst and Process DevelopmentsChemical Reviews, 2008
- Physical Properties and Intermolecular Dynamics of an Ionic Liquid Compared with Its Isoelectronic Neutral Binary SolutionThe Journal of Physical Chemistry A, 2005
- Ionic Liquids--Solvents of the Future?Science, 2003
- Influence of Water on the Orientation of Cations at the Surface of a Room-Temperature Ionic Liquid: A Sum Frequency Generation Vibrational Spectroscopic StudyThe Journal of Physical Chemistry B, 2003
- Effect of a Novel Free Radical Scavenger, Edaravone (MCI-186), on Acute Brain InfarctionCerebrovascular Diseases, 2003